About Lir Bio Advisory

---

Dr Kilian Kelly is the founder of Lir Bio Advisory, bringing over 20 years of biopharmaceutical R&D, regulatory, and executive leadership experience to clients. 

Across his career, Kilian has led all aspects of drug development. In addition to his initial specialisation in regulatory affairs, he has overseen manufacturing, preclinical, and global clinical development programs. His experience encompasses multiple product classes and therapeutic areas,  and key jurisdictions including the USA, EU, UK and Australia. 

Kilian most recently served as CEO and Managing Director of ASX-listed Cynata Therapeutics, where he led the world's first completed clinical trial with an induced pluripotent stem cell (iPSC)-derived product. He remains on the Cynata Board as a Non-Executive Director. Kilian  previously held senior regulatory and clinical development roles at Mesoblast, Biota Pharmaceuticals, Amgen, and AstraZeneca. He is the author of over 20 peer-reviewed publications in leading journals including Nature Medicine and Frontiers in Immunology, and a regular speaker at local and international conferences. 

Kilian holds a PhD in Pharmaceutical Sciences and a Master of Pharmacy and is a Graduate of the Australian Institute of Company Directors (AICD). He is a Member of the Royal College of Pharmacy (RCPharm), the Regulatory Affairs Professionals Society (RAPS), the International Society of Cell and Gene Therapy (ISCT) and the International Society of Stem Cell Research (ISSCR).

linkedin.com/in/kiliankelly

Lir Bio Advisory exists to help biotech companies move from complex science to real-world outcomes — combining deep global research and development expertise with genuine, hands-on delivery.